Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Plasma cell leukemia is a rare and aggressive hematologic malignancy characterized by the presence of malignant plasma cells in peripheral blood and bone marrow. It accounts for approximately 0.1–0.6% of plasma cell disorders in the United States, according to Shagun Singh et al., 2025. According to plasma cell leukemia epidemiology forecast by Expert Market Research, hematologic malignancy burden remains significant due to poor prognosis and rapid disease progression globally.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Plasma Cell Leukemia – Number of Cases by Year

Read more about this report - Request a Free Sample

Plasma Cell Leukemia Epidemiology Forecast Report Coverage

Expert Market Research's “Plasma Cell Leukemia Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of plasma cell leukemia. It projects the future incidence and prevalence rates of plasma cell leukemia cases across various populations. The study covers age, gender, and type as major determinants of the plasma cell leukemia population. The report highlights patterns in the prevalence of plasma cell leukemia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of plasma cell leukemia in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Plasma Cell Leukemia Understanding: Disease Overview

Plasma cell leukemia is an ultra-rare and highly aggressive plasma cell disorder in which abnormal plasma cells circulate in the peripheral blood and infiltrate the bone marrow. It typically presents in two forms: primary plasma cell leukemia, which develops de novo, and secondary plasma cell leukemia, which evolves from pre-existing multiple myeloma. The disease is driven by genetic and cytogenetic abnormalities leading to uncontrolled plasma cell proliferation. It is a plasma cell disorder with rapid progression and high mortality.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Region

India

High-Risk Population

Elderly patients

Key Diagnostic Method

Peripheral blood smear, flow cytometry, and bone marrow biopsy

Major Risk Factor

Progression from multiple myeloma and high-risk cytogenetic abnormalities

Major gap in the market

Underdiagnosis due to rarity and lack of standardized early screening criteria

Plasma Cell Leukemia Epidemiology Perspective

The plasma cell leukemia epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the plasma cell leukemia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for plasma cell leukemia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Shagun Singh et al., 2025, Plasma Cell Leukemia accounts for nearly 0.1–0.6% of plasma cell disorders in the United States, highlighting its extreme rarity and frequent underdiagnosis at the global level.

Gender-Specific Cases of the Disease

As per Shammas Bajwa et al., 2025, the disease shows a near-balanced distribution with 48% male and 52% female patients, indicating minimal gender-based incidence variation across reported cohorts.

Age-Specific Cases of the Disease

As per clinical evidence reported in 2025 studies, Plasma Cell Leukemia primarily affects elderly individuals, with a median age of diagnosis around 66 years, and most cases occurring after 60 years of age.

Ethnicity-Wise Cases of the Disease

According to Shammas Bajwa et al., 2025 (SEER data), cases are predominantly reported in White populations (63.7%), followed by Black (20.67%), Hispanic (10.67%), and other minority groups.

Mortality and Survival Analysis of the Disease

As per Shammas Bajwa et al., 2025, Plasma Cell Leukemia demonstrates extremely poor outcomes with a median survival of ~6 months, 1-year survival of 37.9%, and 5-year survival of only 11%, reflecting its aggressive clinical course.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Primary Plasma Cell Leukemia

Accounts for approximately 1–2% of newly diagnosed multiple myeloma cases; characterized by de novo onset and rapid disease progression.

Secondary Plasma Cell Leukemia

Develops from relapsed or refractory multiple myeloma; rarer in occurrence but associated with extremely poor prognosis and treatment resistance.

Plasma Cell Leukemia – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Plasma Cell Leukemia Epidemiology

The plasma cell leukemia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

According to Shagun Singh et al., 2025, plasma cell leukemia accounts for approximately 0.1–0.6% of plasma cell disorders in the United States. Epidemiologically, its distribution aligns with the national multiple myeloma burden, which serves as the primary precursor population for plasma cell leukemia cases, reflecting its presence across established plasma cell neoplasm registries.

Germany

According to Klaus Martin Kortüm et al., 2026, multiple myeloma in Germany shows age-standardized mortality rates of 1.8 per 100,000 females and 2.9 per 100,000 males. Plasma cell leukemia is documented within national hematologic malignancy records as part of the plasma cell neoplasm continuum, contributing a minimal proportion to overall disease distribution.

France

According to European cohort data cited by Hira Mian et al., 2024, Plasma Cell Leukemia cases are identified within multiple myeloma cohorts, including those with cytogenetic patterns such as t(14;16). Its epidemiological distribution is recorded within specialized plasma cell disorder studies across France and surrounding European populations.

Italy

In Italy, multiple myeloma constitutes a significant component of hematologic malignancy reporting. Plasma Cell Leukemia is captured within plasma cell neoplasm surveillance frameworks, representing advanced disease spectrum observations in clinical and registry-based datasets.

Spain

Spain follows the European multiple myeloma incidence range of approximately 4.5–6.0 cases per 100,000 persons annually. Plasma cell leukemia is represented within national hematology datasets as part of advanced plasma cell disorder progression patterns documented in clinical registries.

United Kingdom

According to Pfizer, around 6,000 multiple myeloma cases are diagnosed annually in the United Kingdom, representing the foundational disease pool associated with plasma cell leukemia epidemiology. Recorded cases of Plasma Cell Leukemia are observed within advanced plasma cell disorder datasets, consistent with the broader Multiple Myeloma disease spectrum.

Japan

According to GSK, Japan reports over 7,200 new multiple myeloma cases annually. Plasma cell leukemia cases are recorded within national hematologic cancer datasets as part of the broader Multiple Myeloma disease continuum, reflecting established clinical reporting patterns.

India

According to Nupur Das et al., 2024, multiple myeloma incidence in India is approximately 1 per 100,000 individuals, with an increasing urban trend. Plasma cell leukemia is documented within tertiary care and registry-based hematology data as part of plasma cell disorder reporting in the country.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The epidemiological understanding of plasma cell leukemia remains limited due to its extreme rarity and lack of standardized diagnostic screening protocols. A major gap exists in early detection, particularly among high-risk multiple myeloma patients who progress to leukemic transformation. In many regions, especially low- and middle-income countries, underreporting and limited registry infrastructure further obscure true disease burden. Emerging opportunities include advanced flow cytometry-based screening, genomic risk stratification, and integration of real-world evidence databases. Expansion of rare cancer registries and improved global surveillance systems represent key unmet needs in this epidemiological landscape.

Plasma Cell Leukemia: Treatment Overview

Management of plasma cell leukemia requires intensive combination therapy due to its highly aggressive nature. Standard treatment includes proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies to achieve rapid disease control. Eligible patients may undergo autologous stem cell transplantation to improve survival outcomes. In refractory or relapsed cases, emerging therapies such as CAR-T cell therapy and novel immunotherapeutic combinations are being evaluated. Despite therapeutic advances, relapse remains common, necessitating continuous monitoring and individualized treatment strategies. A key targeted therapy approach plays an important role in improving response rates and extending progression-free survival.

Key Questions Answered

  • What is the current and projected burden of plasma cell leukemia across the 8 major markets?
  • Which countries across the 8 major markets account for the highest plasma cell leukemia patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of plasma cell leukemia across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of plasma cell leukemia across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of plasma cell leukemia across the 8 major markets?
  • How do major comorbidities and risk factors influence plasma cell leukemia epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of plasma cell leukemia across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the plasma cell leukemia landscape across the 8 major markets?
  • Which therapeutic areas linked to plasma cell leukemia are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the plasma cell leukemia epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on plasma cell leukemia epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for plasma cell leukemia across the 8 major markets?

Scope of the Plasma Cell Leukemia Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of plasma cell leukemia based on several factors.
  • Plasma Cell Leukemia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The plasma cell leukemia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Cancer Supportive Care Drugs Market

Cancer Therapeutics Market

Cancer Screening Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us